These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 10827164)

  • 1. Mutations within the E2 and NS5A protein in patients infected with hepatitis C virus type 3a and correlation with treatment response.
    Sarrazin C; Kornetzky I; Rüster B; Lee JH; Kronenberger B; Bruch K; Roth WK; Zeuzem S
    Hepatology; 2000 Jun; 31(6):1360-70. PubMed ID: 10827164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quasispecies heterogeneity of the carboxy-terminal part of the E2 gene including the PePHD and sensitivity of hepatitis C virus 1b isolates to antiviral therapy.
    Sarrazin C; Bruckner M; Herrmann E; Rüster B; Bruch K; Roth WK; Zeuzem S
    Virology; 2001 Oct; 289(1):150-63. PubMed ID: 11601926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutations in the E2-PePHD and NS5A region of hepatitis C virus type 1 and the dynamics of hepatitis C viremia decline during interferon alfa treatment.
    Berg T; Mas Marques A; Höhne M; Wiedenmann B; Hopf U; Schreier E
    Hepatology; 2000 Dec; 32(6):1386-95. PubMed ID: 11093746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutations in the NS5A and E2-PePHD region of hepatitis C virus type 1b and correlation with the response to combination therapy with interferon and ribavirin.
    Hung CH; Lee CM; Lu SN; Lee JF; Wang JH; Tung HD; Chen TM; Hu TH; Chen WJ; Changchien CS
    J Viral Hepat; 2003 Mar; 10(2):87-94. PubMed ID: 12614464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutations within the hepatitis C virus genotype 1b E2-PePHD domain do not correlate with treatment outcome.
    Gaudy C; Lambelé M; Moreau A; Veillon P; Lunel F; Goudeau A
    J Clin Microbiol; 2005 Feb; 43(2):750-4. PubMed ID: 15695675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutations in E2-PePHD, NS5A-PKRBD, NS5A-ISDR, and NS5A-V3 of hepatitis C virus genotype 1 and their relationships to pegylated interferon-ribavirin treatment responses.
    Muñoz de Rueda P; Casado J; Patón R; Quintero D; Palacios A; Gila A; Quiles R; León J; Ruiz-Extremera A; Salmerón J
    J Virol; 2008 Jul; 82(13):6644-53. PubMed ID: 18448540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutations in the NS5A and E2-PePHD regions of hepatitis C virus genotype 1b and response to combination therapy of interferon plus ribavirin.
    Yang SS; Lai MY; Chen DS; Chen GH; Kao JH
    Liver Int; 2003 Dec; 23(6):426-33. PubMed ID: 14986817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic heterogeneity of hepatitis C virus (HCV) in clinical strains of HIV positive and HIV negative patients chronically infected with HCV genotype 3a.
    Bagaglio S; Bruno R; Lodrini S; De Mitri MS; Andreone P; Loggi E; Galli L; Lazzarin A; Morsica G
    J Biol Regul Homeost Agents; 2003; 17(2):153-61. PubMed ID: 14518715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of the PKR-eIF2alpha phosphorylation homology domain (PePHD) of hepatitis C virus genotype 1 in HIV-coinfected patients by ultra-deep pyrosequencing and its relationship to responses to pegylated interferon-ribavirin treatment.
    Bolcic F; Sede M; Moretti F; Westergaard G; Vazquez M; Laufer N; Quarleri J
    Arch Virol; 2012 Apr; 157(4):703-11. PubMed ID: 22270759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longitudinal analysis of the 5'UTR, E2-PePHD and NS5A-PKRBD genomic regions of hepatitis C virus genotype 1a in association with the response to peginterferon and ribavirin therapy in HIV-coinfected patients.
    Bolcic F; Laufer N; Torres C; Cassino L; Reynoso R; Quarleri J
    Antiviral Res; 2012 Aug; 95(2):72-81. PubMed ID: 22683884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of sequence configurations of the ISDR, PKR-binding domain, and V3 region as predictors of response to induction interferon-alpha and ribavirin therapy in chronic hepatitis C infection.
    Murphy MD; Rosen HR; Marousek GI; Chou S
    Dig Dis Sci; 2002 Jun; 47(6):1195-205. PubMed ID: 12064791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutations in the E2-PePHD region of hepatitis C virus genotype-3a and correlation with response to interferon and ribavirin combination therapy in Pakistani patients.
    Afzal S; Idrees M; Akram M; Awan Z; Khubaib B; Aftab M; Fatima Z; Badar S; Hussain A
    Virol J; 2010 Dec; 7():377. PubMed ID: 21194456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutations in the NS5A gene are associated with response to interferon+ribavirin combination therapy in patients with chronic hepatitis C virus 3a infection.
    Ullah S; Rehman HU; Idrees M
    Eur J Gastroenterol Hepatol; 2013 Oct; 25(10):1146-51. PubMed ID: 23611896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutations in the protein kinase-binding domain of the NS5A protein in patients infected with hepatitis C virus type 1a are associated with treatment response.
    Sarrazin C; Berg T; Lee JH; Rüster B; Kronenberger B; Roth WK; Zeuzem S
    J Infect Dis; 2000 Feb; 181(2):432-41. PubMed ID: 10669323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quasispecies of hepatitis C virus genotype 1 and treatment outcome with peginterferon and ribavirin.
    Jardim AC; Yamasaki LH; de Queiróz AT; Bittar C; Pinho JR; Carareto CM; Rahal P; Mello IM
    Infect Genet Evol; 2009 Jul; 9(4):689-98. PubMed ID: 19063998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequence analysis of PePHD within HCV E2 region and correlation with resistance of interferon therapy in Japanese patients infected with HCV genotypes 2a and 2b.
    Saito T; Ito T; Ishiko H; Yonaha M; Morikawa K; Miyokawa A; Mitamura K
    Am J Gastroenterol; 2003 Jun; 98(6):1377-83. PubMed ID: 12818284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequencing of E2 and NS5A regions of HCV genotype 3a in Brazilian patients with chronic hepatitis.
    Malta Fde M; Medeiros-Filho JE; Azevedo RS; Gonçalves L; Silva LC; Carrilho FJ; Pinho JR
    Mem Inst Oswaldo Cruz; 2010 Feb; 105(1):92-8. PubMed ID: 20209336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of the genetic heterogeneity of the ISDR and PePHD regions of hepatitis C virus on the response to interferon therapy in chronic hepatitis C.
    Puig-Basagoiti F; Sáiz JC; Forns X; Ampurdanès S; Giménez-Barcons M; Franco S; Sánchez-Fueyo A; Costa J; Sánchez-Tapias JM; Rodés J
    J Med Virol; 2001 Sep; 65(1):35-44. PubMed ID: 11505441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutation frequency of NS5A in patients vertically infected with HCV genotype 1 predicts sustained virological response to peginterferon alfa-2b and ribavirin combination therapy.
    Jenke AC; Moser S; Orth V; Zilbauer M; Gerner P; Wirth S
    J Viral Hepat; 2009 Dec; 16(12):853-9. PubMed ID: 19682316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic variability of hepatitis C virus in chronically infected patients with viral breakthrough during interferon-ribavirin therapy.
    Vuillermoz I; Khattab E; Sablon E; Ottevaere I; Durantel D; Vieux C; Trepo C; Zoulim F
    J Med Virol; 2004 Sep; 74(1):41-53. PubMed ID: 15258967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.